DACHDNC MEETING JANUARY 16, 2014 Education and Training Subcommittee Don Bailey, Chair Beth Tarini, Co-Chair.

Slides:



Advertisements
Similar presentations
SCID Review Discussion. Decision Matrix Key Questions 1.This is the overarching question for the evidence review: Is there direct evidence that screening.
Advertisements

A New Vision for Chronic Osteoarthritis Management A Call to Action from the Chronic Osteoarthritis Management Initiative (COAMI) Prepared by the United.
Exercise Swaps Community Emergency Response Team.
Family Centered Approach Hussain Ali Maseeh, Psy.D. Director of SEDIC.
Decision Criteria and Process Advisory Committee on Heritable Disorders in Newborns and Children February 26-27, 2009.
ADHD Assessment and Treatment in Primary Care Jodi Polaha, Ph.D. Assistant Professor, Pediatrics Munroe-Meyer Institute University of Nebraska Medical.
Draft manuscript: “Implementing Point-of-Care Newborn Screening” From the SACHDNC Follow-up & Treatment Sub-committee 1/27/2012 Nancy S. Green, MD Associate.
Treuman Katz Center for Pediatric Bioethics Conference Newborn Screening: The Future Revolution Beth A. Tarini, MD, MS Assistant Professor Child.
Early Hearing Detection and Intervention (EHDI) ~ Challenges and Opportunities ~
Definition of a Consumer One that consumes, especially one that acquires goods or services for direct use or ownership rather than for resale or use in.
Pervasive Developmental Disorders (Autism Spectrum Disorders): Early Screening & Diagnostic Assessment Laura Grofer Klinger, Ph.D. University of Alabama.
Dan Farkas Project Manager Autism Diagnosis Education Pilot Project. Ohio Chapter, American Academy of Pediatrics.
AUSTIM By : Deshonda Reed WHAT IS IT ?  Autism or autism spectrum is a developmental disorder where a child’s normal developmental and social skills.
Dr Catherine Taylor GPST2 Familial Hypercholesterolaemia.
Fragile x syndrome By Jordon Nagel.
Is it a Learning Disability or Vision Problem? The Eye M.D.’s role in screening and treating children to support school and life success Joint Policy Statement.
CHILD PSYCHIATRY Fatima Al-Haidar Professor, child & adolescent psychiatrist College of medicine - KSU.
Illinois Children’s Healthcare Foundation CHILDREN’S MENTAL HEALTH INITIATIVE Building Systems of Care: Community by Community Fostering Creativity Through.
“If you had a problem in the Black community and you brought in a group of White people to discuss how to solve it, almost nobody would take that panel.
Chapter 17 Nursing Diagnosis
REAL-START : Risk Evaluation of Autism in Latinos (Screening Tools and Referral Training) Assuring No Child Enters Kindergarten With an Undetected Developmental.
Diane Schilder, EdD and Jessica Young, PhD Education Development Center, Inc. Quality Rating and Improvement System (QRIS) Provisional Standards Study.
Decision Support for Quality Improvement
Setting the Stage for Change Drafting Maine’s State Plan for Individuals with ASD Nancy Cronin, MA ASD Systems Change Initiative Coordinator.
Introduction In March of this year, the Center for Disease control estimated the incidence of Autism Spectrum Disorders to be 1 in 50, an increase from.
Duchenne Muscular Dystrophy: Cardiac Management. Introduction Aim: early detection and treatment of deterioration in heart muscle function Cardiac disease.
Education and Training Subcommittee Report SACHDNC Advisory Committee Meeting May 17-18, 2012.
A Conceptual Framework for Co- Occurring Disorders within a Behavioral Health Care System Reference: National Dialogue on Co-occurring Mental Health and.
Janice Berry Edwards, PhD, LICSW, LCSW-C, BCD, ACSW
Screening Implementation: Referral and Follow-up What Do You Do When the Screening Test Is of Concern? Paul H. Lipkin, MD D-PIP Training Workshop June.
PKS Kids Family Weekend Friday, June 25, 2010 Francis Filloux, MD Meghan Candee, MD MS Division of Child Neurology, Department of Pediatrics, University.
Evidence Evaluation & Methods Workgroup: Developing a Decision Analysis Model Lisa A. Prosser, PhD, MS September 23, 2011.
Session Fertility and Pregnancy FL-BBM Specific questions Risk of premature ovarian failure Ability to become pregnant Safety of pregnancy.
Proposed Changes to Advisory Committee Processes Sara Copeland, MD Designated Federal Official Secretary’s Advisory Committee on Heritable Disorders in.
Creating a Model Curriculum in the United States Samuel Keim University of Arizona.
Evidence Review Group: Past to Present James M. Perrin, MD Professor of Pediatrics, Harvard Medical School MGH Center for Child and Adolescent Health Policy.
Recommendation to ACHDNC for Newborn Screening for X-linked Adrenoleukodystrophy Fred Lorey, Ph.D. Don Bailey, Ph.D. Liaisons to the Condition Review Workgroup.
GOVERNOR’S EARLY CHILDHOOD ADVISORY COUNCIL (ECAC) September 9, 2014.
Sudipta Sen 2 nd June 2015 INTEGRATED/COLLABORATIVE CARE IN ADHD MANAGEMENT.
PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE PCORI Board of Governors Meeting Washington, DC September 24, 2012 Anne Beal, MD, MPH, Chief Operating Officer.
Vermont’s Approach to Creating a State Autism Plan March 28, 2012 Clare McFadden, Autism Specialist.
Nick Cooksey Period 8. Autistic disorder This disorder usually develops during the first three years of life. Someone with autism would appear to in there.
Evaluation of the Indiana ECCS Initiative. State Context Previous Early Childhood System Initiatives –Step Ahead –Building Bright Beginnings SPRANS Grant.
Issues in Developmental Disabilities Epilepsy in the Intellectually and Developmentally Disabled Discussion with Christopher M. Inglese, M.D. and Susan.
Unit 15: Screening. Unit 15 Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
Canadian Best Practice Recommendations for Stroke Care Recommendation 1: Public Awareness and Patient Education (Updated 2008)
By the end of 2 years (24 months) Use 2- to 4-word phrases Follow simple instructions Become more interested in other children Point to object or picture.
“Focusing on the Process” Jeff Schmidt MD.  Recommendation #1: Children ages 4-18 who present with academic underachievement, behavior problems or.
Module 8: Assessment Summaries using Child Studies.
ALL ABOUT AUTISM We Care Services. WHAT IS AUTISM?  Autism is a serious developmental disorder that challenges the ability to communicate and interact.
Services for Individuals with Autism Spectrum Disorder – Minnesota’s New Benefit Age and Disabilities Odyssey Conference June 17, 2013.
Training for organisations participating in Peer Review of Paediatric Diabetes.
Faculty Disclosure I do not have a significant financial relationship with the manufacturers of commercial products and/or providers of commercial services.
Screening Tests: A Review. Learning Objectives: 1.Understand the role of screening in the secondary prevention of disease. 2.Recognize the characteristics.
About Newborn Screening  Newborn Screening Facts - A brief introduction to the most important information on newborn screening.
Clinical Quality Improvement: Achieving BP Control
Stages of Research and Development
Behavioural and emotional problems in young children with intellectual disabilities and/or autism: Implications for Early Intervention Richard Hastings.
Copyright © 2016, Canadian Cardiovascular Society
EEG characteristics & yield in evaluation of first non-febrile seizure in children in Qatar Abdulhafeez M Khair, Khalid Ibrahim, Rana Alshami, Ahmed Veten,
The Centre for Community-Driven Research
The Child and Youth Psychiatric Consult Project of Iowa (CYC-I)
Diagnostic testing is genetic testing to diagnose a childhood condition or conditions that can be treated medically during childhood. An example is retinoblastoma.
ENQA Agency Reviews – main changes from the old review process
Early Childhood Special Education
Disability diagnosis & Primary Care Management
Chapter 2 Nursing Process
A Quality Improvement Project to Improve the Usage of Universal Lipid Screening Guidelines at a Federally Qualified Health Center in the Southern United.
Mental Health Navigator
Presentation transcript:

DACHDNC MEETING JANUARY 16, 2014 Education and Training Subcommittee Don Bailey, Chair Beth Tarini, Co-Chair

AGENDA Introductions and “2-minute updates” from committee members Wilson’s Disease – issues and considerations for childhood screening -Sihoun Hahn, MD, PhD, University of Washington Discussion of nomination guidance, available materials, next steps

Six Questions for Each Condition What is the typical pattern of identification of children with this condition? What problems exist with the current pattern of identification, problems that could be ameliorated to some extent by earlier identification? Would population screening outside of the newborn period be at all feasible or desirable? In the absence of population screening, what could be the likely best case scenario for earlier identification? What level of effort would be required to substantially change the current paradigm – minimal, moderate, substantial, or heroic? Which stakeholder groups would need to be engaged in any discussions about altering current practice?

What is the typical pattern of identification of children with this condition? Fragile X SyndromeLong QTWilson’s Disease Parents begin noticing problems around 9-12 months Boys are typically diagnosed with a developmental delay around 24 months Average age of FXS diagnosis is around 36 months for boys Girls, especially those who are mildly affected with no affected male siblings are identified later or not at all ECG done in asymptomatic individual Syncopal event Unexplained sudden death in a young individual Identification of a family member Suspicious family history (e.g., SIDS, seizures, syncope) Most likely to be diagnosed by pediatricians if jaundice, then would order liver enzyme tests, vital marker tests, then refer to GI/renal specialists. Begin noticing symptoms between 6- 20yrs. Neurological symptoms, eye abnormalities within adolescence, 15-25yrs.

What problems exist with the current pattern of identification,? Fragile X SyndromeLong QTWilson’s Disease Parents experience a lengthy, costly, and frustrating diagnostic odyssey Children miss the opportunity to participate in early intervention programs About 30% of families have a second child with FXS before the first child is diagnosed First presentation can be sudden death Variable and non- specific symptom presentation often means a long diagnostic process and many individuals are never diagnosed (possibly 50%) With the current delay in diagnosis, liver damage and other serious conditions.

Would population screening outside of the newborn period be at all feasible or desirable? Fragile X SyndromeLong QTWilson’s Disease Full population screening at another age would be very challenging, especially if the test were a stand- alone test. The most likely scenario would be if it became standard practice to do a population-based panel screen for a variety of disorders at some other point during childhood. Yes IF predictive of clinical severity Feasible, but would require a higher level of effort.

In the absence of population screening, what is the best case scenario for early identification? Fragile X SyndromeLong QTWilson’s Disease All pediatricians follow the APA guidelines for screening at 9, 18, and 30 months Any questionable screen is immediately followed by a complete evaluation Any child with a documented delay is immediately referred for genetic testing Best case scenario is months diagnosis for most severely affected males Screening for symptoms in individual Reviewing family history Increasing the awareness so that any patients with unexplained liver or neurological problems get tested for Wilson’s. Goal, to reduce the time between first symptoms and diagnosis.

What effort would be required to substantially change the current paradigm? Fragile X SyndromeLong QTWilson’s Disease Substantial – the main way this would work is if pediatricians themselves requested genetic testing, rather than referring to specialists (e.g., neurologist, developmental behavioral pediatrician, medical geneticist) Substantial A substantial effort, involving training pediatricians/family practitioner to pay attention to these signs and get testing. Neuropsychiatric problems would be harder, clinicians wouldn’t look to Wilson Disease as the initial issue. Develop a gene-based panel based on symptomology.

Which stakeholders would need to be engaged in discussions about altering current practice? Fragile X SyndromeLong QTWilson’s Disease Pediatricians Early intervention programs Developmental evaluation centers Cardiologists Geneticists Primary care physicians Patients and families 1 st line: pediatricians, general practitioners, 2 nd line: ophthalmologists, neurologists, psychiatrists.

Next Steps Finalize tables comparing the three conditions Summarize major issues/themes that have emerged from this work Final report to Committee in May

Priority C: Provide better guidance for advocacy groups and others regarding the nomination and review process Problems to be solved  Increase public transparency for what we do and the rationale for decisions made  Support future nominators in preparing successful application packages

Condition Review Guidance Timeline Summer, 2012SACHDNC report of activity timeline Fall-Spring, 2013Draft documents prepared by Atlas Research Summer, 2013CRW and E&T document revision September, 2013Further discussion of draft document September, 2013Atlas conducted interviews with 4 advocates

Themes from advocate interviews Great appreciation for the work of the committee and the systematic approach to decision-making The nomination form and the matrix portray a deceptively simple process and decision guidelines, behind which is enormous complexity and work A big challenge for everyone is that we have a standardized process that in reality has to be individualized for each condition Advocates need to realize how much work they need to do, the most important being to have a steering committee of experts and stakeholders, and a champion who will guide and lead the process

Themes from advocate interviews (continued) There are terms that advocates do not know (e.g., “analytical validity”) and concepts that advocates and researchers might see differently (e.g., “treatment” or “benefit”) – clear definitions would help An instruction manual would be useful Ideally, advocates and nominators would have someone available to to guide them, including specific advice on next steps and data needed Especially needed is advice on whether the nominated condition is “truly ready to be competitive.” Lack of clarity on sources of funding to do the work needed to provide the evidence required The process takes too long and the committee will not be able to conduct reviews with sufficient expediency as the number of nominations increases

So where are we? What do we have right now?  Web site description of process  Nomination form  Kemper et al. article What do we need now?  “Navigator” to respond to questions and help provide guidance for nominators  Hyperlinks on the nomination form to explain terms and provide further details about what is needed Who will do it?